Alpha Cognition (ACOG) Stock Overview
A biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ACOG Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alpha Cognition Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.41 |
| 52 Week High | US$10.88 |
| 52 Week Low | US$4.50 |
| Beta | 2.33 |
| 1 Month Change | 40.40% |
| 3 Month Change | 29.58% |
| 1 Year Change | -20.13% |
| 3 Year Change | 48.00% |
| 5 Year Change | -52.94% |
| Change since IPO | -55.15% |
Recent News & Updates
ACOG: Phase 4 Tolerability Study Will Drive Future Alzheimer’s Launch Traction
The updated analyst price target for Alpha Cognition shifts from about $20 to roughly $14.67, as analysts factor in revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E, while still highlighting the market opportunity for Zunveyl in treating mild to moderate Alzheimer's dementia. Analyst Commentary Recent Street research on Alpha Cognition focuses on how Zunveyl, its prodrug of galantamine for mild to moderate Alzheimer’s dementia, might translate into commercial traction and support the revised valuation framework behind the updated price target.
ACOG: Early Dementia Therapy Launch Will Drive Bullish Repricing Potential
Analysts have adjusted their 12 month price target for Alpha Cognition to $12 from $14, citing early commercialization of Zunveyl for mild to moderate Alzheimer's dementia and what they view as a significant market opportunity, with high patient and prescriber willingness to try the therapy. Analyst Commentary Recent research coverage on Alpha Cognition has focused on the early commercialization of Zunveyl and the perceived market opportunity in mild to moderate Alzheimer's dementia.Recent updates
ACOG: Phase 4 Tolerability Study Will Drive Future Alzheimer’s Launch Traction
The updated analyst price target for Alpha Cognition shifts from about $20 to roughly $14.67, as analysts factor in revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E, while still highlighting the market opportunity for Zunveyl in treating mild to moderate Alzheimer's dementia. Analyst Commentary Recent Street research on Alpha Cognition focuses on how Zunveyl, its prodrug of galantamine for mild to moderate Alzheimer’s dementia, might translate into commercial traction and support the revised valuation framework behind the updated price target.ACOG: Early Dementia Therapy Launch Will Drive Bullish Repricing Potential
Analysts have adjusted their 12 month price target for Alpha Cognition to $12 from $14, citing early commercialization of Zunveyl for mild to moderate Alzheimer's dementia and what they view as a significant market opportunity, with high patient and prescriber willingness to try the therapy. Analyst Commentary Recent research coverage on Alpha Cognition has focused on the early commercialization of Zunveyl and the perceived market opportunity in mild to moderate Alzheimer's dementia.
Long Term Care Adoption And Real World Studies Will Transform This Cognitive Therapy Narrative
Catalysts About Alpha Cognition Alpha Cognition develops and commercializes therapies for cognitive disorders, with a primary focus on Alzheimer’s disease through its oral treatment ZUNVEYL. What are the underlying business or industry changes driving this perspective?Payer Friction And Slow Adoption Will Challenge Alzheimer’s Therapy Before Long Term Potential Emerges
Catalysts About Alpha Cognition Alpha Cognition is a biopharmaceutical company focused on commercializing ZUNVEYL for mild to moderate Alzheimer’s disease and advancing related formulations and indications. What are the underlying business or industry changes driving this perspective?We Think Alpha Cognition (NASDAQ:ACOG) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We're Interested To See How Alpha Cognition (NASDAQ:ACOG) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Shareholder Returns
| ACOG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.5% | -2.0% | 0.1% |
| 1Y | -20.1% | 34.9% | 20.3% |
Return vs Industry: ACOG underperformed the US Biotechs industry which returned 34.9% over the past year.
Return vs Market: ACOG underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| ACOG volatility | |
|---|---|
| ACOG Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACOG has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACOG's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 71 | Michael McFadden | www.alphacognition.com |
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.
Alpha Cognition Inc. Fundamentals Summary
| ACOG fundamental statistics | |
|---|---|
| Market cap | US$183.12m |
| Earnings (TTM) | -US$25.42m |
| Revenue (TTM) | US$10.83m |
Is ACOG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACOG income statement (TTM) | |
|---|---|
| Revenue | US$10.83m |
| Cost of Revenue | US$1.35m |
| Gross Profit | US$9.47m |
| Other Expenses | US$34.90m |
| Earnings | -US$25.42m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 87.52% |
| Net Profit Margin | -234.84% |
| Debt/Equity Ratio | 0% |
How did ACOG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/13 04:40 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alpha Cognition Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Nazibur Rahman | Maxim Group |
| Ryan Deschner | Raymond James & Associates |